Search

Your search keyword '"Cortesi E."' showing total 785 results

Search Constraints

Start Over You searched for: Author "Cortesi E." Remove constraint Author: "Cortesi E."
785 results on '"Cortesi E."'

Search Results

1. Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: Long-term Results of a Prospective Phase II Study

3. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

4. Characterization of Small Airway Obstruction Diversity in COPD

5. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

7. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

8. Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial

9. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

10. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

11. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

12. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

13. 127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma

14. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

21. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

22. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

30. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

32. Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: A real-world observational cohort study [Risultati a lungo termine della terapia di mantenimento con pemetrexed nei pazienti affetti da tumore polmonare non a piccole cellule in stadio avanzato e istologia non squamosa: Uno studio osservazionale di coorte condotto nella pratica clinica del mondo reale]

33. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer

34. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

35. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population

36. Erratum to “30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease” [Lung Cancer 122 (2018) 165–170]

37. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

39. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

42. Cancer patients as `experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO)

45. BRCA screening among Jewish community of Rome

46. 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study

47. 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment

Catalog

Books, media, physical & digital resources